Featured Research

from universities, journals, and other organizations

Important Milestone In Therapeutic Cloning: Advanced Cell Technology Reports Publication Of Results Of Human Somatic Cell Nuclear Transfer And Parthenogenesis

Date:
November 26, 2001
Source:
Advanced Cell Technology
Summary:
Advanced Cell Technology, Inc. has announced publication of its research on human somatic cell nuclear transfer and parthenogenesis. The report, published in today’s Journal of Regenerative Medicine, provides the first proof that reprogrammed human cells can supply tissue for transplantation.

Worcester, MA – November 25, 2001 – Advanced Cell Technology, Inc. (ACT) today announced publication of its research on human somatic cell nuclear transfer and parthenogenesis. The report, published in today’s Journal of Regenerative Medicine, provides the first proof that reprogrammed human cells can supply tissue for transplantation.

Human embryonic stem (ES) cells, and other cells derived from the inner cell mass of the preimplantation embryo are totipotent, that is, they are capable of forming any cell or tissue in the human body. While numerous human ES cell lines are now in existence, they are of little value in human transplantation, as they would be rejected by a patient as foreign. Human therapeutic cloning has the potential to solve this problem by providing cells that are an exact genetic match for the patient.

ACT’s paper reports preliminary studies on two means of manufacturing such cells. The first method is parthenogenesis. In this technique an egg cell is activated without being fertilized by a sperm cell. A patient in need of a particular cell or tissue type provides the egg cell, the activated egg cell forms a preimplantation embryo, and the resulting stem cells are differentiated into the type of tissue the patient needs. The paper reports success in activating egg cells in this manner to form many-celled embryos resembling blastocysts. The paper does not report data on stem cell isolation.

In a second series of studies, the company performed somatic cell nuclear transfer (cloning) to form preimplantation embryos. In this instance, human egg cells were prepared by removing their DNA and adding the DNA from a human somatic (body) cell. The paper reports that the somatic nuclei showed evidence of reprogramming to an embryonic state as evidenced by pronuclear development (a type of nucleus observed only in the fertilized egg) and by early embryonic development to the six-cell stage. Again, the company did not report on stem cell isolation.

“Our preliminary results add to the weight of evidence that human cell reprogramming is possible,” said Jose B. Cibelli, Ph.D., D.VM., Vice-President of Research at ACT and the first author of the report. “We understand that these are early and preliminary results, but given the importance of this emerging field of medicine we decided to publish our results now.”

The company’s goal in applying cloning to human medicine is to create stem cells capable of differentiating into a variety of cells, such as heart cells, neurons, blood cells or islets for transplant therapies. “These are exciting preliminary results,” said Robert P. Lanza, M.D., Vice President of Medical and Scientific Development at ACT and an author on the paper. “This work sets the stage for human therapeutic cloning as a potentially limitless source of immune-compatible cells for tissue engineering and transplantation medicine. Our intention is not to create cloned human beings, but rather to make lifesaving therapies for a wide range of human disease conditions, including diabetes, strokes, cancer, AIDS, and neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease.”

“Human therapeutic cloning could be used for a host of age-related diseases,” said Michael D. West, Ph.D. the company’s CEO and an author of the paper, “if the human cells behave as animal cells have in previous studies, we may have found a means of rebuilding the lifespan of cells at the same time. This would allow us to supply young cells of any kind, identical to the patient, that could be used to address the tidal wave of age-related disease that will accompany the aging of the population.”

Researchers from Advanced Cell Technology collaborated with scientists from Duncan Holly Biomedical of Somerville, Massachusetts on the paper. The other authors are Kerrianne Cunniff of ACT, and Ann A. Kiessling and Charlotte Richards.

Advanced Cell Technology is a biotechnology company focused on discovering and developing cloning technology for human medicine and agriculture.


Story Source:

The above story is based on materials provided by Advanced Cell Technology. Note: Materials may be edited for content and length.


Cite This Page:

Advanced Cell Technology. "Important Milestone In Therapeutic Cloning: Advanced Cell Technology Reports Publication Of Results Of Human Somatic Cell Nuclear Transfer And Parthenogenesis." ScienceDaily. ScienceDaily, 26 November 2001. <www.sciencedaily.com/releases/2001/11/011126000857.htm>.
Advanced Cell Technology. (2001, November 26). Important Milestone In Therapeutic Cloning: Advanced Cell Technology Reports Publication Of Results Of Human Somatic Cell Nuclear Transfer And Parthenogenesis. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2001/11/011126000857.htm
Advanced Cell Technology. "Important Milestone In Therapeutic Cloning: Advanced Cell Technology Reports Publication Of Results Of Human Somatic Cell Nuclear Transfer And Parthenogenesis." ScienceDaily. www.sciencedaily.com/releases/2001/11/011126000857.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins